About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID 		Sppl3tm1Itl
targeted mutation 1, Ingenious Targeting Laboratory
MGI:6467467
Summary 4 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cn1
 		Sppl3tm1Itl/Sppl3tm1Itl
Ncr1tm1.1(icre)Viv/Ncr1+ 		involves: 129S/SvEv * C57BL/6 MGI:6515783
cn2
 		Sppl3tm1Itl/Sppl3tm1Itl
Commd10Tg(Vav1-icre)A2Kio/Commd10+ 		involves: 129S/SvEv * C57BL/6 * C57BL/10 * CBA/Ca MGI:6515779
cn3
 		Sppl3tm1Itl/Sppl3em1Pomz
Ncr1tm1.1(icre)Viv/Ncr1+ 		involves: 129S/SvEv * C57BL/6 * C57BL/6J MGI:6515792
cn4
 		Sppl3tm1Itl/Sppl3tm1Itl
Edil3Tg(Sox2-cre)1Amc/Edil3+ 		involves: 129S/SvEv * C57BL/6 * CBA MGI:6515777


Genotype
MGI:6515783
cn1
Allelic
Composition		 Sppl3tm1Itl/Sppl3tm1Itl
Ncr1tm1.1(icre)Viv/Ncr1+
Genetic
Background		 involves: 129S/SvEv * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ncr1tm1.1(icre)Viv mutation (1 available); any Ncr1 mutation (40 available)
Sppl3tm1Itl mutation (0 available); any Sppl3 mutation (75 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
immune system
abnormal NK cell differentiation ( J:280182 )
• mice show subtle changes in the expression of NK cell surface receptors and a defect in NK cell maturation with a 5-fold reduction of CD27+CD11b+ NK cells in spleen and a 2.7-fold loss of CD27+CD11b+ NK cells in the bone marrow
increased immature NK cell number ( J:280182 )
• mice show a 1.3-fold increase in the number of immature CD27+CD11b- NK cells in bone marrow but no significant change in spleen
decreased NK cell number ( J:280182 )
• number of NK cells (Lin-CD122+DX5+) is decreased 4-fold in spleen and 1.5-fold in the bone marrow
decreased mature NK cell number ( J:280182 )
• mice show a 9-fold reduction of mature CD27-CD11b+ NK cells in spleen, and 4-fold loss of CD27-CD11b+ NK cells in the bone marrow
abnormal NK cell physiology ( J:280182 )
• annexin V staining showed a modest reduction of cell death CD11b- NK cells in the bone marrow relative to controls (10% vs 14%) but no significant change in splenic CD11b- NK cells
• mice show a 2-fold reduction in the % of proliferating Ki67+CD11b- NK cells in the bone marrow, with no change in the % of Ki67+CD11b+ cells
• splenic CD11b- NK cells show no change in Ki67 staining, and even a small increase in the CD11b+ fraction relative to controls (10.8% vs 6.8%)
• CD11b+ NK cells show a 2-fold increase in annexin V staining in the bone marrow and a 3-fold increase in spleen
• however, activation of mTOR in response to IL-15 stimulation is normal in immature NK cells
impaired natural killer cell mediated cytotoxicity ( J:280182 )
• mice exhibit reduced clearance of MHC class I-deficient tumors in vivo; 48 h after i.p. injection, recovery of RMA/s tumor cells is 6.5% versus 1.8% in control mice
• in an in vitro YAC-1 target lysis assay, splenic NK cells (DX5+) show 53% of the cytotoxic activity seen in control mice at a 2:1 E:T ratio

hematopoietic system
abnormal NK cell differentiation ( J:280182 )
• mice show subtle changes in the expression of NK cell surface receptors and a defect in NK cell maturation with a 5-fold reduction of CD27+CD11b+ NK cells in spleen and a 2.7-fold loss of CD27+CD11b+ NK cells in the bone marrow
increased immature NK cell number ( J:280182 )
• mice show a 1.3-fold increase in the number of immature CD27+CD11b- NK cells in bone marrow but no significant change in spleen
decreased NK cell number ( J:280182 )
• number of NK cells (Lin-CD122+DX5+) is decreased 4-fold in spleen and 1.5-fold in the bone marrow
decreased mature NK cell number ( J:280182 )
• mice show a 9-fold reduction of mature CD27-CD11b+ NK cells in spleen, and 4-fold loss of CD27-CD11b+ NK cells in the bone marrow
abnormal NK cell physiology ( J:280182 )
• mice show a 2-fold reduction in the % of proliferating Ki67+CD11b- NK cells in the bone marrow, with no change in the % of Ki67+CD11b+ cells
• splenic CD11b- NK cells show no change in Ki67 staining, and even a small increase in the CD11b+ fraction relative to controls (10.8% vs 6.8%)
• annexin V staining showed a modest reduction of cell death CD11b- NK cells in the bone marrow relative to controls (10% vs 14%) but no significant change in splenic CD11b- NK cells
• CD11b+ NK cells show a 2-fold increase in annexin V staining in the bone marrow and a 3-fold increase in spleen
• however, activation of mTOR in response to IL-15 stimulation is normal in immature NK cells
impaired natural killer cell mediated cytotoxicity ( J:280182 )
• mice exhibit reduced clearance of MHC class I-deficient tumors in vivo; 48 h after i.p. injection, recovery of RMA/s tumor cells is 6.5% versus 1.8% in control mice
• in an in vitro YAC-1 target lysis assay, splenic NK cells (DX5+) show 53% of the cytotoxic activity seen in control mice at a 2:1 E:T ratio




Genotype
MGI:6515779
cn2
Allelic
Composition		 Sppl3tm1Itl/Sppl3tm1Itl
Commd10Tg(Vav1-icre)A2Kio/Commd10+
Genetic
Background		 involves: 129S/SvEv * C57BL/6 * C57BL/10 * CBA/Ca
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Commd10Tg(Vav1-icre)A2Kio mutation (3 available); any Commd10 mutation (24 available)
Sppl3tm1Itl mutation (0 available); any Sppl3 mutation (75 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
mortality/aging ( J:280182 )
N
• mice are born at normal Mendelian ratios and appear healthy

immune system
immune system phenotype ( J:280182 )
N
• mice have normal numbers of T (CD3+CD4+, CD3+CD8+) and B cells (CD19+B220+) in spleen
abnormal NK cell differentiation ( J:280182 )
• mice show reduced expression of several NK cell surface receptors and a severe defect in NK cell maturation, with a 3-fold loss of CD27+CD11b+ in spleen and a 2-fold loss of CD27+CD11b+ in the bone marrow, indicating a partial block in maturation at the CD27+CD11b- stage
increased immature NK cell number ( J:280182 )
• mice show a 2-fold increase in the total number of immature CD27+CD11b- NK cells in the spleen and bone marrow
decreased NK cell number ( J:280182 )
• mice exhibit reduced numbers of peripheral NK cells; the number of NK cells (Lin-CD122+DX5+) is decreased ~2-fold in spleen and 3-fold in liver
• however, NK cell number is normal in the bone marrow
decreased mature NK cell number ( J:280182 )
• mice show a 2.6-fold decrease in the most mature CD27-CD11b+ NK cells in bone marrow, and a 4.9-fold reduction of CD27-CD11b+ cells in spleen
impaired natural killer cell mediated cytotoxicity ( J:280182 )
• mice exhibit reduced clearance of MHC class I-deficient tumors in vivo; 48 h after i.p. injection, recovery of RMA/s tumor cells is 7% versus 1% in control mice
• in an in vitro YAC-1 target lysis assay, splenic NK cells (DX5+) show ~60% of the cytotoxic activity seen in control mice across a range of E:T ratios

hematopoietic system
hematopoietic system phenotype ( J:280182 )
N
• mice have normal numbers of T (CD3+CD4+, CD3+CD8+) and B cells (CD19+B220+) in spleen
abnormal NK cell differentiation ( J:280182 )
• mice show reduced expression of several NK cell surface receptors and a severe defect in NK cell maturation, with a 3-fold loss of CD27+CD11b+ in spleen and a 2-fold loss of CD27+CD11b+ in the bone marrow, indicating a partial block in maturation at the CD27+CD11b- stage
increased immature NK cell number ( J:280182 )
• mice show a 2-fold increase in the total number of immature CD27+CD11b- NK cells in the spleen and bone marrow
decreased NK cell number ( J:280182 )
• mice exhibit reduced numbers of peripheral NK cells; the number of NK cells (Lin-CD122+DX5+) is decreased ~2-fold in spleen and 3-fold in liver
• however, NK cell number is normal in the bone marrow
decreased mature NK cell number ( J:280182 )
• mice show a 2.6-fold decrease in the most mature CD27-CD11b+ NK cells in bone marrow, and a 4.9-fold reduction of CD27-CD11b+ cells in spleen
impaired natural killer cell mediated cytotoxicity ( J:280182 )
• mice exhibit reduced clearance of MHC class I-deficient tumors in vivo; 48 h after i.p. injection, recovery of RMA/s tumor cells is 7% versus 1% in control mice
• in an in vitro YAC-1 target lysis assay, splenic NK cells (DX5+) show ~60% of the cytotoxic activity seen in control mice across a range of E:T ratios




Genotype
MGI:6515792
cn3
Allelic
Composition		 Sppl3tm1Itl/Sppl3em1Pomz
Ncr1tm1.1(icre)Viv/Ncr1+
Genetic
Background		 involves: 129S/SvEv * C57BL/6 * C57BL/6J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ncr1tm1.1(icre)Viv mutation (1 available); any Ncr1 mutation (40 available)
Sppl3em1Pomz mutation (0 available); any Sppl3 mutation (75 available)
Sppl3tm1Itl mutation (0 available); any Sppl3 mutation (75 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
mortality/aging ( J:280182 )
N
• mice are born in Mendelian ratios and survive without any overt phenotype

immune system
abnormal NK cell differentiation ( J:280182 )
• mice show a defect in NK cell maturation with a 1.8-fold reduction of CD27+CD11b+ NK cells in the bone marrow and a 3-fold loss of CD27+CD11b+ NK cells in spleen
increased immature NK cell number ( J:280182 )
• mice show a 1.4-fold increase in the number of immature CD27+CD11b- NK cells in bone marrow but no significant change in spleen
decreased NK cell number ( J:280182 )
• mice exhibit reduced numbers of peripheral NK cells with a 2.9-fold reduction of NK cell number in spleen
• however, NK cell number is normal in the bone marrow
decreased mature NK cell number ( J:280182 )
• mice show a 6-fold reduction of mature CD27-CD11b+ NK cells in spleen, and 3-fold loss of CD27-CD11b+ NK cells in the bone marrow

hematopoietic system
abnormal NK cell differentiation ( J:280182 )
• mice show a defect in NK cell maturation with a 1.8-fold reduction of CD27+CD11b+ NK cells in the bone marrow and a 3-fold loss of CD27+CD11b+ NK cells in spleen
increased immature NK cell number ( J:280182 )
• mice show a 1.4-fold increase in the number of immature CD27+CD11b- NK cells in bone marrow but no significant change in spleen
decreased NK cell number ( J:280182 )
• mice exhibit reduced numbers of peripheral NK cells with a 2.9-fold reduction of NK cell number in spleen
• however, NK cell number is normal in the bone marrow
decreased mature NK cell number ( J:280182 )
• mice show a 6-fold reduction of mature CD27-CD11b+ NK cells in spleen, and 3-fold loss of CD27-CD11b+ NK cells in the bone marrow




Genotype
MGI:6515777
cn4
Allelic
Composition		 Sppl3tm1Itl/Sppl3tm1Itl
Edil3Tg(Sox2-cre)1Amc/Edil3+
Genetic
Background		 involves: 129S/SvEv * C57BL/6 * CBA
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Edil3Tg(Sox2-cre)1Amc mutation (5 available); any Edil3 mutation (43 available)
Sppl3tm1Itl mutation (0 available); any Sppl3 mutation (75 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
neonatal lethality, incomplete penetrance ( J:280182 )
• although mice are born in expected Mendelian ratios, a substantial proportion of mice die of undetermined causes shortly after birth
postnatal lethality, incomplete penetrance ( J:280182 )
• only about 10% survive to weaning

growth/size/body
decreased birth body size ( J:280182 )




Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
12/10/2024
MGI 6.24 		The Jackson Laboratory